# Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

> **NCT00729898** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 243 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT00729898
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729898, "Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*